期刊文献+

柔红霉素、阿糖胞苷作用于NB4细胞的体外实验研究 被引量:2

Effect of daunorubicin and cytarabine on cell line NB4
原文传递
导出
摘要 目的探讨柔红霉素(DNR)联合阿糖胞苷(Ara-C)和单用DNR对急性早幼粒细胞白血病(APL)细胞株NB4与另一急性髓系白血病(M2)细胞株HL-60生长抑制率、凋亡率的比较。方法用MTT法和流式细胞术分别检测NB4与HL-60细胞的生长抑制率和细胞凋亡率;采用瑞特染色法观察细胞形态。结果两组药物(DNR单药组和双药组)对NB4细胞的生长抑制率[单药组为(35.73±6.82)%,双药组为(36.75±3.82)%]、凋亡率[单药组为(22.55±3.62)%,双药组为(21.24±5.82)%]差异均无统计学意义(P〉0.05);而对HL-60细胞的抑制率[单药组为(62.31±1.80)%,双药组为(67.17±2.07)%]、凋亡率[单药组为(41.51±0.89)%,双药组为(48.05±0.92)%]的差异均有统计学意义(P值分别〈0.01和〈0.05);形态学检测显示,各组细胞形态学上均出现凋亡特征性改变。结论从细胞水平说明,DNR联合Ara—C与单用DNR对APL的疗效差异无统计学意义,且后者的临床不良反应明显轻于前者,因此支持单用DNR的治疗方案。 Objective To explore whether daunorubicin(DNR) combined with cytosine arabinoside (Ara-C) and DNR alone have similar effect on acute promyelocytic leukemia(APL) cell line NB4 and acute myeloblastic leukemia cell line HL-60 in vitro, Methods Cell morphology, cells viability, and cell apoptosis ( Annexin-Ⅴ by flow cytometry assay) were analysed, Results After incubation with DNR plus Ara-C for 24 hours, NB4 cell viability [ ( 36.75±3.82) % ] ( n = 6) and cell apoptosis rate [ (21.24 ± 5.82) % ] ( n = 3 ) did not change significantly compared to that treated with DNR alone for 24 hours [ ( 35.73 ± 6.28 ) %, (22.55±3.26)% ,respectively] (P 〉0.05). However, HL-60 cell viability [ (67. 17 ± 2.07 )% ] and cell apoptosis rate [ (48.05±0. 92)% ] changed significantly in DNR plus Ara-C group compared with DNR alone [ (63.31 ± 1.80 ) %, ( 41.51 ± 0.89) %, respectively ] ( P 〈 0.01 and 〈 0.05, respectively ). Conclusion DNR plus Ara-C and DNR alone have similar effect on NB4 cells, but have different effect on HL-60 cells.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2007年第4期247-249,共3页 Chinese Journal of Hematology
关键词 柔红霉素 阿糖胞苷 白血病 早幼粒细胞 急性 细胞系 白血病 Cytosine arabinoside Daunorubicin Leukemia, promyelocytic,acute Cell lines,leukemia
  • 相关文献

参考文献9

  • 1Tallman MS, Andersen JW, Schiffer CA, et al. All-trans refinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.Blood, 2002, 100:4298-4302.
  • 2Ortega JJ, Madero L, Martin G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol, 2005, 20:7632-7640.
  • 3Sanz MA, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood, 2004,104:3490-3493.
  • 4Schlenk RF, Germing U, Hartmann F, et al. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia, 2005, 19:978-983.
  • 5Avvisati G, Petti MC, Lo-Coco F, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood, 2002, 100:3141-3146.
  • 6Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-basod consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. Blood, 1999, 94:3015 -3021.
  • 7AI Bahar S, Pandita R, Bavishi K, et al. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Indian J Cancer, 2004, 41:125-128.
  • 8Sanz MA, Coco FL, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 2000, 96 : 1247-1253.
  • 9Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients ( > or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multieenter group GIMEMA with ATRA and idarubicin ( AIDA ) protocols. Leukemia, 2003, 17 :1085-1090.

同被引文献17

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部